# Journey Medical Corp: financial statements, quarterly

DERM · Nasdaq · CIK 1867066 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/derm.md) · [Financials](/companies/derm/financials.md) · [Filings](/companies/derm/filings.md) · [Insiders](/companies/derm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/derm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.3](/filings/0001410578-24-001877.md) | [15.3 d](/filings/0001410578-25-000490.md) | [13.0](/filings/0001410578-25-001296.md) | [14.9](/filings/0001410578-25-001703.md) | [14.6](/filings/0001104659-25-110457.md) | [12.6 d](/filings/0001104659-26-034629.md) | [13.1](/filings/0001104659-26-060297.md) | [15.0](/filings/0001104659-26-094948.md) | [17.0](/filings/0001104659-25-110457.md) | [16.1 d](/filings/0001104659-26-034629.md) | [15.9](/filings/0001104659-26-060297.md) | [17.8](/filings/0001104659-26-094948.md) |
| Cost of revenue | $m | [6.4](/filings/0001410578-24-001877.md) | [2.2 d](/filings/0001410578-25-000490.md) | [6.8](/filings/0001410578-24-000817.md) | [6.5](/filings/0001410578-24-001326.md) | [5.3](/filings/0001410578-24-001877.md) | [2.2 d](/filings/0001104659-26-034629.md) | [4.8](/filings/0001104659-26-060297.md) | [4.9](/filings/0001104659-26-094948.md) | not reported | not reported | [6.2](/filings/0001104659-26-060297.md) | [6.1](/filings/0001104659-26-094948.md) |
| Research and development | $m | [2.2](/filings/0001410578-24-001877.md) | [1.5 d](/filings/0001410578-25-000490.md) | [7.9](/filings/0001410578-25-001296.md) | [0.9](/filings/0001410578-25-001703.md) | [0.8](/filings/0001104659-25-110457.md) | [0.2 d](/filings/0001104659-26-034629.md) | [0.0](/filings/0001104659-26-060297.md) | [0.0 d](/filings/0001104659-26-094948.md) | [0.3](/filings/0001104659-25-110457.md) | [0.2 d](/filings/0001104659-26-034629.md) | not reported | [0.1](/filings/0001104659-26-094948.md) |
| Selling, general and administrative | $m | [8.6](/filings/0001410578-24-001877.md) | [9.8 d](/filings/0001410578-25-000490.md) | [8.4](/filings/0001410578-25-001296.md) | [10.3](/filings/0001410578-25-001703.md) | [11.4](/filings/0001104659-25-110457.md) | [10.1 d](/filings/0001104659-26-034629.md) | [10.6](/filings/0001104659-26-060297.md) | [11.9](/filings/0001104659-26-094948.md) | [12.1](/filings/0001104659-25-110457.md) | [9.9 d](/filings/0001104659-26-034629.md) | [10.1](/filings/0001104659-26-060297.md) | [10.9](/filings/0001104659-26-094948.md) |
| Operating income | $m | [17.2](/filings/0001410578-24-001877.md) | [(2.1) d](/filings/0001410578-25-000490.md) | [(10.1)](/filings/0001410578-25-001296.md) | [(2.9)](/filings/0001410578-25-001703.md) | [(2.9)](/filings/0001104659-25-110457.md) | [2.2 d](/filings/0001104659-26-034629.md) | [(3.3)](/filings/0001104659-26-060297.md) | [(2.9)](/filings/0001104659-26-094948.md) | [(1.5)](/filings/0001104659-25-110457.md) | [(0.4) d](/filings/0001104659-26-034629.md) | [(1.5)](/filings/0001104659-26-060297.md) | [0.5](/filings/0001104659-26-094948.md) |
| Interest expense | $m | [0.3](/filings/0001410578-23-002335.md) | [0.0 d](/filings/0001410578-24-000347.md) | [0.5](/filings/0001410578-24-000817.md) | [0.6](/filings/0001410578-25-001703.md) | [0.8](/filings/0001104659-25-110457.md) | [0.8 d](/filings/0001104659-26-034629.md) | [0.9](/filings/0001104659-26-060297.md) | [0.9](/filings/0001104659-26-094948.md) | [0.9](/filings/0001104659-25-110457.md) | [0.9 d](/filings/0001104659-26-034629.md) | [0.9](/filings/0001104659-26-060297.md) | [0.9](/filings/0001104659-26-094948.md) |
| Income tax | $m | [0.1](/filings/0001410578-24-001877.md) | [0.1 d](/filings/0001410578-25-000490.md) | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001104659-26-094948.md) | [0.0 d](/filings/0001104659-25-110457.md) | [0.0 d](/filings/0001104659-26-034629.md) | not reported | [0.0](/filings/0001104659-26-094948.md) |
| Net income | $m | [16.8](/filings/0001410578-24-001877.md) | [(2.1) d](/filings/0001410578-25-000490.md) | [(10.4)](/filings/0001410578-25-001296.md) | [(3.4)](/filings/0001410578-25-001703.md) | [(2.4)](/filings/0001104659-25-110457.md) | [1.5 d](/filings/0001104659-26-034629.md) | [(4.1)](/filings/0001104659-26-060297.md) | [(3.8)](/filings/0001104659-26-094948.md) | [(2.3)](/filings/0001104659-25-110457.md) | [(1.2) d](/filings/0001104659-26-034629.md) | [(2.2)](/filings/0001104659-26-060297.md) | [(0.3)](/filings/0001104659-26-094948.md) |
| Diluted EPS | $ per share | [0.80](/filings/0001410578-24-001877.md) | not reported | [(0.53)](/filings/0001410578-25-001296.md) | [(0.17)](/filings/0001410578-25-001703.md) | [(0.12)](/filings/0001104659-25-110457.md) | not reported | [(0.18)](/filings/0001104659-26-060297.md) | [(0.16)](/filings/0001104659-26-094948.md) | [(0.09)](/filings/0001104659-25-110457.md) | not reported | [(0.08)](/filings/0001104659-26-060297.md) | [(0.01)](/filings/0001104659-26-094948.md) |
| Basic EPS | $ per share | [0.91](/filings/0001410578-24-001877.md) | not reported | [(0.53)](/filings/0001410578-25-001296.md) | [(0.17)](/filings/0001410578-25-001703.md) | [(0.12)](/filings/0001104659-25-110457.md) | not reported | [(0.18)](/filings/0001104659-26-060297.md) | [(0.16)](/filings/0001104659-26-094948.md) | [(0.09)](/filings/0001104659-25-110457.md) | not reported | [(0.08)](/filings/0001104659-26-060297.md) | [(0.01)](/filings/0001104659-26-094948.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.7](/filings/0001410578-23-002335.md) | [27.4](/filings/0001410578-25-000490.md) | [24.1](/filings/0001410578-24-000817.md) | [23.9](/filings/0001410578-24-001326.md) | [22.5](/filings/0001410578-24-001877.md) | [20.3](/filings/0001104659-26-034629.md) | [21.1](/filings/0001410578-25-001296.md) | [20.3](/filings/0001410578-25-001703.md) | [24.9](/filings/0001104659-25-110457.md) | [24.1](/filings/0001104659-26-094948.md) | [27.2](/filings/0001104659-26-060297.md) | [25.6](/filings/0001104659-26-094948.md) |
| Current assets | $m | [44.7](/filings/0001410578-23-002335.md) | [56.5](/filings/0001410578-25-000490.md) | [47.0](/filings/0001410578-24-000817.md) | [46.5](/filings/0001410578-24-001326.md) | [46.2](/filings/0001410578-24-001877.md) | [48.2](/filings/0001104659-26-034629.md) | [54.0](/filings/0001410578-25-001296.md) | [51.3](/filings/0001410578-25-001703.md) | [56.4](/filings/0001104659-25-110457.md) | [66.9](/filings/0001104659-26-094948.md) | [65.0](/filings/0001104659-26-060297.md) | [72.8](/filings/0001104659-26-094948.md) |
| Total assets | $m | [65.9](/filings/0001410578-23-002335.md) | [76.8](/filings/0001410578-25-000490.md) | [66.6](/filings/0001410578-24-000817.md) | [65.2](/filings/0001410578-24-001326.md) | [64.0](/filings/0001410578-24-001877.md) | [80.2](/filings/0001104659-26-034629.md) | [85.0](/filings/0001410578-25-001296.md) | [81.2](/filings/0001410578-25-001703.md) | [85.2](/filings/0001104659-25-110457.md) | [94.6](/filings/0001104659-26-094948.md) | [91.5](/filings/0001104659-26-060297.md) | [98.4](/filings/0001104659-26-094948.md) |
| Current liabilities | $m | [48.5](/filings/0001410578-23-002335.md) | [41.9](/filings/0001410578-25-000490.md) | [38.9](/filings/0001410578-24-000817.md) | [34.1](/filings/0001410578-24-001326.md) | [33.3](/filings/0001410578-24-001877.md) | [35.2](/filings/0001104659-26-034629.md) | [40.2](/filings/0001410578-25-001296.md) | [40.5](/filings/0001410578-25-001703.md) | [39.7](/filings/0001104659-25-110457.md) | [37.4](/filings/0001104659-26-094948.md) | [37.8](/filings/0001104659-26-060297.md) | [45.8](/filings/0001104659-26-094948.md) |
| Total liabilities | $m | [48.5](/filings/0001410578-23-002335.md) | [56.5](/filings/0001410578-25-000490.md) | [53.6](/filings/0001410578-24-000817.md) | [53.9](/filings/0001410578-24-001326.md) | [53.1](/filings/0001410578-24-001877.md) | [60.2](/filings/0001104659-26-034629.md) | [63.4](/filings/0001410578-25-001296.md) | [61.9](/filings/0001410578-25-001703.md) | [59.3](/filings/0001104659-25-110457.md) | [62.7](/filings/0001104659-26-094948.md) | [60.7](/filings/0001104659-26-060297.md) | [66.2](/filings/0001104659-26-094948.md) |
| Long-term debt | $m | [0.0](/filings/0001410578-23-002335.md) | [14.6](/filings/0001410578-25-000490.md) | [14.7](/filings/0001410578-24-000817.md) | [19.7](/filings/0001410578-24-001326.md) | [19.8](/filings/0001410578-24-001877.md) | [24.9](/filings/0001104659-26-034629.md) | [23.1](/filings/0001410578-25-001296.md) | [21.4](/filings/0001410578-25-001703.md) | [19.5](/filings/0001104659-25-110457.md) | [25.3](/filings/0001104659-26-094948.md) | [22.9](/filings/0001104659-26-060297.md) | [20.5](/filings/0001104659-26-094948.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | [1.9](/filings/0001410578-25-001296.md) | [3.8](/filings/0001410578-25-001703.md) | [5.6](/filings/0001104659-25-110457.md) | not reported | [2.5](/filings/0001104659-26-060297.md) | [5.0](/filings/0001104659-26-094948.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [17.4](/filings/0001410578-24-001877.md) | [20.4](/filings/0001104659-26-034629.md) | [13.0](/filings/0001410578-25-001703.md) | [11.3](/filings/0001104659-25-110457.md) | [10.9](/filings/0001104659-25-110457.md) | [20.1](/filings/0001104659-26-094948.md) | [21.5](/filings/0001104659-26-094948.md) | [19.2](/filings/0001104659-26-094948.md) | [25.9](/filings/0001104659-25-110457.md) | [31.9](/filings/0001104659-26-094948.md) | [30.8](/filings/0001104659-26-094948.md) | [32.1](/filings/0001104659-26-094948.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [18.7 d](/filings/0001410578-24-001877.md) | [(16.5) d](/filings/0001410578-25-000490.md) | [(5.0)](/filings/0001410578-25-001296.md) | [(5.2) d](/filings/0001410578-25-001703.md) | [(1.2) d](/filings/0001104659-25-110457.md) | [2.2 d](/filings/0001104659-26-034629.md) | [(2.8)](/filings/0001104659-26-060297.md) | [(0.9) d](/filings/0001104659-26-094948.md) | [(2.4) d](/filings/0001104659-25-110457.md) | [(6.3) d](/filings/0001104659-26-034629.md) | [2.9](/filings/0001104659-26-060297.md) | [(1.7) d](/filings/0001104659-26-094948.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001410578-24-001877.md) | [0.0 d](/filings/0001410578-25-000490.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.6](/filings/0001410578-23-002335.md) | [17.8](/filings/0001410578-24-000817.md) | [18.0](/filings/0001410578-24-001326.md) | [21.0](/filings/0001410578-24-001877.md) | [19.8](/filings/0001410578-25-001296.md) | [20.0](/filings/0001410578-25-001703.md) | [20.5](/filings/0001104659-25-110457.md) | [22.6](/filings/0001104659-26-060297.md) | [23.3](/filings/0001104659-26-094948.md) | [25.0](/filings/0001104659-25-110457.md) | [27.3](/filings/0001104659-26-060297.md) | [27.5](/filings/0001104659-26-094948.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.